The consortium of philanthropic, non-profit and private sector organisations launched a collaboration that aims to accelerate the development of novel "pan-TB" drug regimens for the treatment of tuberculosis (TB) that are ready for phase 3 development. The regimens will be designed to have little to no drug resistance and an acceptable safety profile, and be better-tolerated, shorter in duration and simpler to use than existing options. Such regimens are intended to be a central component of efforts to address the current complexities and challenges of TB treatment. The members of the Project to Accelerate New Treatments for Tuberculosis (PAN-TB collaboration) - Evotec, GSK, Johnson & Johnson, Otsuka Pharmaceutical Co., Ltd., based in Japan, the Bill & Melinda Gates Medical Research Institute and the Bill & Melinda Gates Foundation - have committed to leveraging their unique assets, resources and scientific expertise to advance the development of novel regimens. "Current tools are insufficient for accelerating and sustaining global progress against TB," said Trevor Mundel, President of Global Health at the Bill & Melinda Gates Foundation. "Innovative partnerships, such as the PAN-TB collaboration, are urgently needed to develop new drugs and treatment regimens that can address TB and advance progress towards achieving global elimination TB goals." TB causes more deaths globally than any other infectious disease, with 10 million new cases and 1.5 million deaths recorded in 2018 alone. TB is responsible for up to a third of all mortality associated with antimicrobial resistance (AMR)., The current regimen for drug-sensitive TB, the most common and easiest to treat form of TB, requires that patients take multiple drugs for six or more months under clinical monitoring. Patients with drug-resistant TB cannot use this regimen and face longer and more complex treatment regimens, often with significant side effects. Currently, patients must undergo additional testing to diagnose drug-resistant TB. The regimens that the PAN-TB collaboration is working to develop could help transform TB care. A shorter and safer novel regimen that can treat TB irrespective of pre-existing drug resistance and with reduced need for drug resistance testing, could provide a significant benefit to both patients and health systems. The PAN-TB collaboration will identify and assess the potential of investigational pan-TB regimens, through phase 2 clinical efficacy studies. Collaborative pre-clinical research activities have begun. Clinical trials will be announced as they are planned. About the Project to Accelerate New Treatments for Tuberculosis The Project to Accelerate New Treatments for Tuberculosis (PAN-TB collaboration) is a first-of-its-kind collaboration among philanthropic, non-profit and private sectors that aims to accelerate the development of an investigational drug regimen capable of treating all forms of tuberculosis. The PAN-TB collaboration will leverage members’ collective assets, resources and scientific expertise to identify and evaluate new drug regimens with an acceptable safety profile, that have the potential to treat both drug-sensitive and drug-resistant TB, and are better-tolerated, shorter in duration and simpler to use than existing options. The collaboration will focus on advancing research through phase 2 clinical efficacy studies in order to identify promising regimens for further development. The PAN-TB collaboration plans to work closely and transparently with the European Regimen Accelerator for Tuberculosis (ERA4TB), which was launched in January 2020. New molecular entities identified by ERA4TB that show promise in initial human studies could later be incorporated into the PAN-TB collaboration’s later-stage, clinical research. Several organisations, including Evotec, GSK and Johnson & Johnson, are members of both projects, which will help to ensure coordination across collaborations toward the common goal of advancing TB drug and regimen development. The founding members of the PAN-TB collaboration are Evotec, GSK, Johnson & Johnson, Otsuka Pharmaceutical Co., Ltd., based in Japan, the Bill & Melinda Gates Medical Research Institute and the Bill & Melinda Gates Foundation. Additional members may be announced in the future. About Tuberculosis TB causes more deaths globally than any other infectious disease, with 10 million new cases and 1.5 million deaths recorded in 2018 alone. Though the number of deaths is falling, it isn't falling fast enough to reach WHO’s global TB elimination goals. The emergence and spread of drug-resistant TB are also urgent concerns. In 2017, drug-resistant TB alone caused 230,000 deaths – one-third of all deaths due to AMR. TB is also the leading cause of death in people living with HIV, accounting for one-third of deaths among HIV-positive people. The world’s most vulnerable are disproportionately affected by TB, with many cases of TB occurring in resource-limited areas. About the Bill & Melinda Gates Medical Research Institute The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organisation conducting clinical research to accelerate product development for diseases and disorders that disproportionately affect the world's poorest populations - malaria, tuberculosis, diarrhea and maternal and newborn child health conditions that combined cause ten deaths every minute. About Evotec Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. We operate worldwide and our more than 2,900 employees provide the highest quality stand-alone and integrated drug discovery and development solutions. About GSK GSK is a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer.